PROGRAM MENU
EDUCATIONAL PROGRAM
WORKSHOPS & SYMPOSIA
CONTINUING EDUCATION
Educational Program
THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.
Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.
Wednesday, October 28th
10:00 - 11:30 AM
|
PLENARY 2: KEY PERSPECTIVES ON SAFE AND EFFECTIVE ANTICOAGULANT THERAPY Chair/Organizer: Anne Rose, Christine Guelcher
Virtual Room 1 This Plenary session will address what are widely viewed as the most important issues for safe and effective anticoagulation therapy. The session will include an expert overview of current and emerging anticoagulant therapies, the public health approach to ensuring anticoagulant medication safety, and issues to consider to minimize both thrombotic and bleeding complications for patients undergoing surgery. |
1 |
Anticoagulant Targets: Overview Of Current And Emerging Therapies Jeff Weitz. McMaster University |
2 |
The Importance Of Patient Safety Considerations: Anticoagulants place in the public health approach to medication safety Charles (Kurt) Mahan. Presbyterian Healthcare Services |
3 |
Minimizing Thrombotic And Bleeding Complications In the Setting of Surgery PJ Devereaux. McMaster University |
12:15 - 1:15 PM
|
CORPORATE LUNCH SYMPOSIUM: DOUBLE FEATURE: OBESITY IN HEMOPHILIA AND A TREATMENT OPTION FOR HEMOPHILIA A
Virtual Room 1 Supported by: Novo Nordisk Pharmaceuticals, Inc. The first part is an interactive program discussing the importance of managing obesity in the hemophilia community. Managing obesity is one of the toughest challenges for health care professionals in general and is often overlooked. This program will feature a discussion on obesity as a disease and how obesity impacts people with hemophilia. Results from a study designed to understand the barriers to initiating and maintaining weight loss in obese patients with hemophilia and to identify insights on the unique challenges of these patients from the perspective of health care professionals will be covered. In the second part, the program will feature aspects of the pathfinder clinical trial program and information on a factor VIII extended half-life product. The program is being moderated by Dr. Stephanie Seremetis and will feature Dr. Meera Chitlur, Dr. Miguel Escobar and Dr. Anthony Auriemma. Please see Prescribing Information We kindly ask that you take a few minutes to complete the survey at end of the presentation |
|
CORPORATE LUNCH SYMPOSIUM: HEMOPHILIA RESEARCH IN THE 21ST CENTURY
Virtual Room 2 Sponsored By: Sanofi Genzyme In this symposium, we will discuss a diverse range of possible approaches to managing hemophilia. We will reexamine what potential outcomes can be achieved for people with hemophilia and consider how we can support our patients on a path toward normalized hemostasis and quality of life. |
2:00 - 3:30 PM
|
EVALUATING FOR VON WILLEBRAND DISEASE Chair/Organizer: William Nichols
Virtual Room 2 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
1 |
Diagnostic testing for von Willebrand disease: Trends and insights from external quality assessments of North American laboratory practices Jameel Abdulrehman. University Health Network |
2 |
Assessment Of Children For Von Willebrand Disease: New Evidence On How Many Times We Need To Test Bhavya Doshi. Children's Hospital of Philadelphia |
3 |
Genetic Testing For Von Willebrand Disease. Update On When It Is Useful Veronica Flood. Medical College of Wisconsin |
NEW INSIGHTS ON COAGULATION Chair/Organizer: Nicole Zantek, Muriel Maurer
Virtual Room 3 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
1 |
New Insights on Factor XIII And Thrombosis Muriel Maurer. University of Louisville |
2 |
Anti-inflammatory Effects Of FVIIa LVM Rao. The University of Texas Health Science Center at Tyler |
3 |
Initiation Of Blood Coagulation James Morrissey. University of Michigan Medical School |
THE CHANGING LANDSCAPE OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM Chair/Organizer: James Douketis
Virtual Room 1 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
1 |
Primary VTE prophylaxis in cancer patients Marc Carrier. Ottawa Hospital Research Institute |
2 |
Treatment of cancer-associated VTE, including special and difficult patient populations. Michael Streiff. Johns Hopkins University School of Medicine |
3 |
Clinical Controversies in Treating Thrombosis Sam Schulman. McMaster University |
4:15 - 5:45 PM
|
DTI USE Chair/Organizer: Luis Meillon, Teresa Bordeaux
Virtual Room 1 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
1 |
DTI Use For Atypical VTE (Splanchnic Bed, Cerebral Vein Thrombosis) And For HIT(T) Rachel Rosovsky. Massachusetts General Hospital |
2 |
DTI use in LVADs, ECMO, Cardiac Cath Jerrold Levy. Duke University School of Medicine |
3 |
DTI Use In Pediatrics Shannon Carpenter. Children's Mercy Hospital |
EMERGING ISSUES IN BLEEDING DISORDERS Chair/Organizer: Michelle Witkop
Virtual Room 2 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
1 |
Genetic Testing For Congenital Thrombocytopenia Syndromes Brian Branchford. University of Colorado School of Medicine and Children's Hospital Colorado |
2 |
Treating Pain In Patients With Bleeding Disorders Tyler Buckner. University of Colorado School of Medicine |
3 |
Anticoagulation For Patients With Bleeding Disorders (Covers VTE Prophy In Ortho Procedures, Rx Of AF, CAD In Bleeding Disorder Pts And PVT In Cirrhotics) Craig Kessler. Georgetown University Medical Center |
UPDATE ON THROMBOTIC MICROANGIOPATHIES Chair/Organizer: Charles Eby, Marian Rollins Raval
Virtual Room 3 Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting. |
1 |
Overview On Thrombotic Thrombocytopenic Purpura Including The Importance Of ADAMTS13 Assays For Diagnosis Sateesh Chonat. Emory University and Children's Healthcare of Atlanta |
2 |
New Insights On The Contributions Of ADAMTS13 And Complement To TTP Pathogenesis From Experimental Models X.Long Zheng. The University of Alabama at Birmingham |
3 |
Clinical And Laboratory Considerations For The Long Term Followup And Treatment Of TTP James George. University of Oklahoma Health Sciences Center |
6:00 - 7:00 PM
|
CORPORATE DINNER SYMPOSIUM: CLINICAL INSIGHTS IN VTE: TREATMENT AND RISK REDUCTION THROUGH PROPHYLAXIS (LIVE ONLY - NOT RECORDED)
Virtual Room 1 Sponsored by: Janssen Pharmaceuticals, Inc. Speaker: Samuel A. Berkman, MD, FACP Clinical Professor of Medicine, Division of Hematology-Oncology UCLA Medical Center Beverly Hills, California This lecture will discuss venous thromboembolism (VTE) prophylaxis, as well as treatment options for patients with deep vein thrombosis and/or pulmonary embolism, and how these treatment options may reduce the risk of recurrent thrombotic events. |
6:15 - 7:00 PM
|
THSNA NETWORKING HAPPY HOUR: TRANSITION TO PRACTICE DISCUSSION FORUM FOR TRAINEES AND THOSE IN THE FIRST FEW YEARS OF PRACTICE. Chair/Organizer: Roona Sinha
Virtual Room 2 This will be an open discussion for trainees and those new in practice to discuss issues they are having or they anticipate having with regards to transition to practice, how to navigate being a staff physician, and how to make the most of the THSNA conference as a transitioning physician! |
7:00 - 8:00 PM
|
BASIC SCIENCE OF THROMBOSIS/ANTICOAGULATION
Virtual Room 3 |
Extracellular Vesicles Derived from Red Blood Cells Activate Microvascular Endothelial Cells and Result in Red Blood Cell Adhesion in Sickle Cell Disease Ran An1, Yuncheng Man1, Jane A. Little2, Umut A. Gurkan1. 1Case Western Reserve University, Cleveland, OH, USA.2The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
Combination of heparin and a FX/FXa aptamer to reduce thrombin generation in models of Cardiopulmonary Bypass Charlene V. Chabata1, 2, James W. Frederiksen2, Ruwan Gunaratne3, Bruce A. Sullenger1, 2. 1Duke University, Department of Pharmacology and Cancer Biology, Durham, NC, USA.2Duke University, Department of Surgery, Durham, NC, USA.3Stanford University, School of Medicine, Palo Alto, CA, USA |
Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as measured by Whole Blood Thromboelastographic Analysis Siddharth Mehrotra1, Debra Hoppensteadt1, Walter Jeske1, Omer Iqbal1, Alfonso Tafur2, Bruce Lewis1, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA.2Northshore Health Systems, Skokie, IL, USA |
Inhibitors Against Procoagulant and Antifibrinolytic Properties of Extracellular Nucleic Acids Sreeparna Vappala1, 2, 8, Manu Thomas Kalathottukaren1, 2, 8, Srinivas Abbina1, 2, 8, Chanel La1, 3, 8, Libin Abraham4, 8, Iren Constantinescu1, 2, 8, Charles A Haynes1, 5, 8, Edward M Conway1, 6, 8, Jayachandran N Kizhakkedathu1, 2, 3, 7, 8. 1Centre for Blood Researc, Vancouver, BC, Canada.2Department of Pathology and Laboratory medicine, Vancouver, BC, Canada.3Department of Chemistry, Vancouver, BC, Canada.4Microbiology and Immunology, Vancouver, BC, Canada.5Chemical a Biological Engineering, Vancouver, BC, Canada.6Department of Medicine, Vancouver, BC, Canada.7The School of Biomedical Engineering, Vancouver, BC, Canada.8University of British Columbia, Vancouver, BC, Canada |
|
LABORATORY 2
Virtual Room 5 |
Order Set Modification Promotes Effective Laboratory Test Utilization in the Diagnosis ofHIT Michael Kimbrell, John Larson, Mikhail Akbashev. Emory University Department of Medicine, Atlanta, GA, USA |
Unreliability of activated partial thromboplastin time to monitor bivalirudin therapy in pediatric extracorporeal life support Vadim Kostousov1, 2, Karen Bruzdoski1, Lisa Hensch1, 2, Shiu-Ki Rocky Hui1, 2, Jun Teruya1, 2. 1Texas Children's Hospital, Houston, TX, USA.2Baylor College of Medicine, Houston, TX, USA |
Serotonin Release Assay by Liquid Mass Spectrometry: A Comparative Laboratory Methods Study Rachel R Leger1, Jennifer A Faber1, Deepti M Warad1, Ravinder J Singh1, Jansen N Seheult2, Rajiv K Pruthi1, Dong Chen1. 1Mayo Clinic, Rochester, MN, USA.2University of Pittsburgh Medical Center, Pittsburgh, PA, USA |
Chromogenic Bethesda Assay Performance in Hemophilia A Patients with and without Emicizumab Connie H Miller1, Brian Boylan1, Amanda B Payne1, Jennifer Driggers1, Christopher J Bean1, HIRS Investigators2. 1Centers for Disease Control and Prevention, Atlanta, GA, USA.2See appendix, HIRS United States |
Biomarkers of intravascular coagulation and fibrinolysis in severe SARS-CoV-2 infection (COVID-19) Jansen N. Seheult1, 2, Michael P. Meyer2, Michelle N. Stram3, Andrea Cortese Hassett2, Alan Wells1, Haris Zia4, Alison Morris5, Janet S. Lee5, Bryan J. McVerry5, Matthew D. Neal6, Georgios Kitsios5, William Bain5. 1Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.2Vitalant Specialty Labs - Coag a MID, Pittsburgh, PA, USA.3Department of Forensic Medicine, New York University, New York, NY, USA.4Internal Medicine Residency Program, University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, USA.5Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.6Pittsburgh Trauma Research Center and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA |
|
PLATELETS AND VON WILLEBRAND FACTOR
Virtual Room 4 |
Adverse bone health and wound healing outcomes in Von Willebrand disease Divyaswathi Citla Sridhar1, 3, Yazan Abou-Ismail2, 3, Maria Pereda1, 3, Lalitha Nayak2, 3, Robert Sidonio Jr4, Sanjay Ahuja1, 3. 1Rainbow Babies a Children's Hospital, Cleveland, OH, USA.2University Hospitals Cleveland Medical Center, Cleveland, OH, USA.3Case Western Reserve University, Cleveland, OH, USA.41Children, Atlanta, GA, USA |
Genotype vs Phenotype:a cross-sectional study examining the incidence of genetic variants in patients with qualitative platelet disorders Kristina/M Haley, Stewart Worthington, Susan Lattimore, Mary Pat Bland, Jody Kujovich. Oregon Health a Science University, Portland, OR, USA |
Platelets as Versatile Effectors of Thromboinflammation in Chronic Myeloproliferative Neoplasms Anandi Krishnan1, Wenfei Du2, Cecelia Perkins3, Zhu Shen4, Jason Gotlib5, James Zehnder6. 1Pathology, Stanford, CA, USA.2Statistics, Stanford, CA, USA.3Hematology, Stanford United States.4Statistics, Stanford, CA, USA.5Hematology, Stanford, CA, USA.6Hematology, Stanford, CA, USA |
|
THROMBOSIS: RISKS
Virtual Room 6 |
Increased Risk of Thrombosis in ALK-Rearranged Lung Cancer Hanny Al-Samkari1, 2, Orly Leiva2, 3, Ibiayi Dagogo-Jack1, 2, Alice Shaw1, 2, Pavan K. Bendapudi1, 2, Jean M. Connors2, 4. 1Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA.2Harvard Medical School, Boston, MA, USA.3Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.4Hematology Division, Brigham and Women's Hospital, Boston, MA, USA |
Effect of race/ethnicity on the risk of cancer-associated venous thromboembolism for three common cancers Tatini Datta, Ann Brunson, Anjlee Mahajan, Theresa Keegan, Ted Wun. Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA |
Reduced calf muscle pump function is a risk factor for venous thromboembolism and mortality Damon / E Houghton, Aneel Ashrani, David Liedl, Ramila Mehta, Paul Wennberg, Waldemar Wysokinski, Thom Rooke, Robert McBane. Mayo Clinic, Rochester, MN, USA |
Low bleeding risk procedures: should we let DOAC be? Muhammad A. Sheikh1, Xiaowen Kong2, Brian Haymart2, Xiaokui Gu2, Scott Kaatz3, Gregory Krol3, Jay Kozlowski4, Musa Dahu5, Mona Ali6, Steven Almany7, Eva Kline-Rogers2, James Froehlich2, Geoffrey D. Barnes2. 1Division of Hospital Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.2Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.3Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA.4Department of Cardiovascular Medicine, Huron Valley Sinai Hospital, Commerce Township, MI, USA.5Heart and Vascular Institute, Spectrum Health System, Grand Rapids, MI, USA.6Department of Pharmacy, Beaumont Hospital, Royal Oak, MI, USA.7Department of Internal Medicine, Beaumont Health, Oakland University School of Medicine, Royal Oak, MI, USA |
Creation of a Real-Time Risk Prediction Model for Pediatric Thrombosis Events Shannon C. Walker1, C. Buddy Creech1, Henry J. Domenico2, Daniel W. Byrne2, Allison P. Wheeler1, 2. 1Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA.2Vanderbilt University Medical Center, Nashville, TN, USA |
7:00 - 7:45 PM
|
VIRTUAL POSTERS - BLOOD COAGULATION AND FIBRINOLYTIC FACTORS
Virtual Room 1 Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the “Ask a Question” option. Note that all questions may not receive a response. |
|
VIRTUAL POSTERS - DISORDERS OF COAGULATION OR FIBRINOLYSIS
Virtual Room 2 Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the “Ask a Question” option. Note that all questions may not receive a response. |